## Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## In the Claims:

What is claimed is:

1. (Currently amended) A compound of formula (I):



(I)

wherein:

$R^1$ represents phenyl which may be optionally substituted by one or more substituents which may be the same or different and which are selected from the group consisting of: halogen; trifluoromethyl; -$C_{1-6}$alkyl optionally substituted by $COOR^{15}$; -$C_{1-6}$alkoxy optionally substituted by $COOR^{15}$; hydroxy; oxo; cyano; -$C_{1-6}$alkyl-cyano; $C_{1-6}$alkenyl optionally substituted by $COOR^{15}$; $C_{3-7}$cycloalkyl; $C_{1-6}$alkylsulfonyl; $C_{1-6}$alkenoxy; $C_{1-6}$alkylthio; $NR^{15}R^{16}$; -$C_{1-6}$alkyl-aryl; aryl; -CO-aryl optionally substituted by halogen; -CO-heteroaryl; -CO-heterocyclyl; $-COOR^{15}$; $-COR^{15}$; $-CONR^{15}R^{16}$ optionally substituted by $C_{1-6}$alkyl, halogen or -$C_{1-6}$alkyl$C_{1-6}$alkoxy; and -$C_{1-6}$alkyl-CO-aryl groups; and in which

$R^{15}$ and $R^{16}$ independently represent hydrogen, $C_{1-6}$alkyl or $C_{3-8}$cycloalkyl or together may be fused to form a 5- to 7-membered non-aromatic heterocyclic ring optionally interrupted by an O or S atom and optionally substituted by a halogen, $C_{1-6}$alkyl or $C_{1-6}$alkyl$C_{1-6}$alkoxy group;

Z represents CO;

r is 0;

p is 1;

m is 0;

$R^3$ represents group of formula (i):



(i)

wherein

f is 0;

g is 2;

h is 1;

k is 0; and

$R^{13}$ represents $C_{1-6}$alkyl or $C_{3-8}$cycloalkyl;

or a pharmaceutically acceptable salt thereof.

~~$R^1$ represents hydrogen, $C_{1-6}$ alkyl, $C_{1-6}$ alkoxy, $C_{3-8}$ cycloalkyl, $C_{1-6}$ alkyl $C_{3-8}$ cycloalkyl, aryl, heterocyclyl, heteroaryl, $C_{1-6}$ alkyl-aryl, $C_{1-6}$ alkyl-heteroaryl, $C_{1-6}$ alkyl-heterocyclyl, -aryl-aryl, -aryl-heteroaryl, -aryl-heterocyclyl, heteroaryl-aryl, -heteroaryl-heteroaryl, -heteroaryl-heterocyclyl, -heterocyclyl-aryl, -heterocyclyl-heteroaryl, -heterocyclyl-heterocyclyl,~~

~~wherein $R^1$ may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, $COOR^{15}$, cyano, $C_{1-6}$ alkyl-cyano, nitro, oxo, trifluoromethyl, trifluoromethoxy, fluoromethoxy, difluoromethoxy, $C_{1-6}$ alkyl (optionally substituted by a $COOR^{15}$ group), $C_{2-6}$ alkenyl (optionally substituted by a $COOR^{15}$ group), $C_{2-6}$ alkynyl (optionally substituted by a $COOR^{15}$ group), $C_{1-6}$ alkoxy (optionally substituted by a $COOR^{15}$ group), pentafluoroethyl, $C_{1-6}$ alkoxy, $C_{2-6}$ alkenoxy, aryl, aryl$C_{1-6}$ alkyl, -CO-aryl (optionally substituted by a halogen atom), -CO-heteroaryl, $C_{1-6}$ alkyl-CO-aryl, aryl$C_{1-6}$ alkoxy, $C_{1-6}$ alkylthio, $C_{1-6}$ alkoxy$C_{1-6}$ alkyl, $C_{3-7}$ cycloalkyl, $C_{3-7}$ cycloalkyl$C_{1-6}$ alkoxy, $C_{1-6}$ alkoxycarbonyl, $C_{1-6}$ alkylsulfonyl, $C_{1-6}$ alkylsulfinyl, $C_{1-6}$ alkylsulfonyloxy, $C_{1-6}$ alkylsulfonyl$C_{1-6}$ alkyl, sulfonyl, arylsulfonyl, arylsulfonyloxy, arylsulfonyl$C_{1-6}$ alkyl, aryloxy, $C_{1-6}$ alkylsulfonamido, $C_{1-6}$ alkylamido, $C_{1-6}$ alkylsulfonamido$C_{1-6}$ alkyl, $C_{1-6}$ alkylamido$C_{1-6}$ alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamido$C_{1-6}$ alkyl, arylcarboxamido$C_{1-6}$ alkyl, aroyl, aroyl$C_{1-6}$ alkyl, aryl$C_{1-6}$ alkanoyl, or a group $-COR^{15}$, $-NR^{15}R^{16}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-NR^{15}SO_2R^{16}$ or $-SO_2NR^{15}R^{16}$, wherein $R^{15}$ and $R^{16}$ independently represent hydrogen, $C_{1-6}$ alkyl or $C_{3-8}$ cycloalkyl or together may be fused to form a 5- to 7- membered non-aromatic heterocyclic ring optionally interrupted by an O or S atom and optionally substituted by a halogen, $C_{1-6}$ alkyl or $-C_{1-6}$ alkyl$C_{1-6}$ alkoxy group;~~

~~Z represents a bond, CO, -CON($R^{10}$)- or $SO_2$, such that when $R^1$ represents hydrogen, Z represents $CONR^{10}$;~~

~~p is 1 or 2;~~

~~m, n and r independently represent 0, 1 or 2;~~

~~$R^2$ represents halogen, $C_{1-6}$ alkyl, $C_{1-6}$ alkoxy, cyano, amino or trifluoromethyl, such that when n represents 2, two $R^2$ groups may instead be linked to form a phenyl ring;~~

~~$R^4$ represents $C_{1-6}$ alkyl, such that when r represents 2, two $R^4$ groups may instead be linked to form a $CH_2$, $(CH_2)_2$ or $(CH_2)_3$ group;~~

~~$R^{10}$ represents hydrogen or $C_{1-6}$ alkyl, or $R^{10}$, together with $R^1$ forms a heterocyclic group;~~

~~$R^3$ represents $-(CH_2)_q-NR^{11}R^{12}$ or a group of formula (i):~~




~~wherein q is 2, 3 or 4;~~

~~$R^{11}$ and $R^{12}$ independently represent $C_{1-6}$ alkyl or $C_{3-8}$ cycloalkyl or together with the nitrogen atom to which they are attached represent an N-linked nitrogen containing heterocyclyl group optionally substituted by one or more $R^{17}$ groups;~~

~~$R^{13}$ represents hydrogen, $C_{1-6}$ alkyl, $-C_{1-6}$ alkyl-$C_{1-6}$ alkoxy, $C_{3-8}$ cycloalkyl, $-C_{1-6}$ alkyl-$C_{3-8}$ cycloalkyl, $-C_{1-6}$ alkyl-aryl or heterocyclyl;~~

~~$R^{14}$ and $R^{17}$ independently represent halogen, $C_{1-6}$ alkyl, haloalkyl, OH, di$C_{1-6}$ alkylamino, $C_{1-6}$ alkoxy or heterocyclyl;~~

~~f and k independently represent 0, 1 or 2;~~

~~g is 0, 1 or 2 and h is 0, 1, 2 or 3, such that g and h cannot both be 0;~~

~~with the proviso that when m represents 1, n and r both represent 0 and $R^3$ represents $-(CH_2)_3$-N-piperidine or $-(CH_2)_3-N(ethyl)_2$, $R^1$-Z represents a group other than methyl, -CO-O-$C(CH_3)_3$ or benzyl;~~

~~and with the proviso that when m, n and r all represent 0, p represents 1, $R^3$ represents $-(CH_2)_3$-N-pyrrolidine or $-(CH_2)_3$-N-piperidine, $R^1$ represents benzyl, Z represents a group other than a bond;~~

~~and with the proviso that when m, n and r all represent 0, p represents 1, $R^3$ represents $-(CH_2)_3$-N-piperidine, $R^1$ represents isopropyl, Z represents a group other than a bond;~~

~~and with the proviso that when m represents 1, n and r both represent 0, p represents 1, $R^3$ represents $-(CH_2)_3$-N-piperidine, $R^4$ represents methyl, isopropyl, aryl or benzyl, Z represents a group other than a bond;~~
~~and with the proviso that when m and n both represent 0, $R^3$ represents $-(CH_2)_3$-N(ethyl)$_2$, p represents 1, r represents 2 and $R^4$ and $R^4$ both represent methyl, Z represents a group other than a bond;~~
~~or a pharmaceutically acceptable salt thereof.~~

2-11. (Cancelled)

Add the following new claims:

12. (New) A compound according to claim 1 wherein $R^1$ is phenyl which may be optionally substituted by 1, 2 or 3 substituents which may be the same or different and which are selected from the group consisting of: chlorine, fluorine, bromine; trifluoromethyl; methyl, ethyl, isopropyl, propyl, t-butyl (optionally substituted by COOH, COOMe or COOEt); methoxy, butoxy, -OCH(Me)$_2$, –OC(Me)$_3$ (optionally substituted by COOH or COOMe); hydroxy; oxo; cyano; –$CH_2$-CN; ethenyl (optionally substituted by COOMe); cyclopentyl; –$SO_2$Me; –$OCH_2CH=CH_2$; –S-ethyl; N(Me)$_2$; benzyl; phenyl; –CO-phenyl (optionally substituted by chlorine); –CO-azetidinyl; –CO-tetrahydropyranyl; COOH, COOMe, COOt-butyl; –CO-methyl, -CO-ethyl, -CO-isopropyl, -CO-cyclopropyl, -CO-cyclobutyl, -CO-cyclopentyl, -CO-cyclohexyl; –$CONH_2$, -CO-pyrrolidinyl, -CO-morpholinyl, -CO-piperazinyl, -CO-piperidinyl, -CO-thiomorpholinyl (optionally substituted by methyl, fluorine and –$CH_2$OMe); or –$CH_2$COphenyl groups;
or a pharmaceutically acceptable salt thereof.

13. (New) A compound according to claim 1 wherein $R^1$ is phenyl substituted by $C_{1-6}$alkylsulfonyl.

14. (New) A compound according to claim 1 wherein $R^1$ is phenyl substituted by $SO_2$Me.

15. (New) A compound according to claim 1 wherein $R^1$ is phenyl substituted by $SO_2Me$ at the para position.

16. (New) A compound according to claim 1 wherein -O-$R^3$ is present at the para position of the phenyl group with respect to the rest of the compound.

17. (New) A compound according to claim 1 wherein $R^{13}$ represents isopropyl, cyclopropyl or cyclobutyl.

18. (New) A compound according to claim 13, wherein $R^{13}$ represents isopropyl, cyclopropyl or cyclobutyl.

19. (New) A compound according to claim 14, wherein $R^{13}$ represents isopropyl, cyclopropyl or cyclobutyl.

20. (New) A compound which is 1-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-4-{[4-(methylsulfonyl)phenyl]carbonyl}piperazine or a pharmaceutically acceptable salt thereof.

21. (New) A pharmaceutical composition which comprises a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

22. (New) A method of treatment of diseases of the upper respiratory tract which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in claims 1 or a pharmaceutically acceptable salt thereof.

23. (New) A method of treatment according to claim 21 in which the disease is allergic rhinitis.

24. (New) A pharmaceutical composition which comprises a compound of formula (I) as defined in claim 18 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

25. (New) A method of treatment of diseases of the upper respiratory tract which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in claims 18 or a pharmaceutically acceptable salt thereof.

26. (New) A method of treatment according to claim 25 in which the disease is allergic rhinitis.

27. (New) A pharmaceutical composition which comprises a compound of formula (I) as defined in claim 19 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

28. (New) A method of treatment of diseases of the upper respiratory tract which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in claims 19 or a pharmaceutically acceptable salt thereof.

29. (New) A method of treatment according to claim 28 in which the disease is allergic rhinitis.